Novo Nordisk A/S (NYSE:NVO) Upgraded at Zacks Research

Zacks Research upgraded shares of Novo Nordisk A/S (NYSE:NVO) from a strong sell rating to a hold rating in a report published on Tuesday,Zacks.com reports.

Several other analysts also recently issued reports on the stock. Weiss Ratings raised shares of Novo Nordisk A/S from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, February 5th. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. The Goldman Sachs Group reiterated a “neutral” rating and set a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research report on Thursday, February 12th. Finally, Deutsche Bank Aktiengesellschaft lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, February 23rd. Four equities research analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the company. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus target price of $49.93.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $38.04 on Tuesday. Novo Nordisk A/S has a one year low of $35.85 and a one year high of $82.57. The company has a 50-day moving average of $50.43 and a two-hundred day moving average of $51.92. The stock has a market cap of $169.83 billion, a price-to-earnings ratio of 10.96 and a beta of 0.73. The company has a debt-to-equity ratio of 0.61, a current ratio of 0.80 and a quick ratio of 0.57.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.90 by $0.11. The business had revenue of $12.43 billion for the quarter, compared to analyst estimates of $11.97 billion. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a dividend yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 23.63%.

Institutional Trading of Novo Nordisk A/S

Institutional investors have recently bought and sold shares of the company. Franklin Resources Inc. raised its stake in shares of Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after purchasing an additional 13,658,867 shares in the last quarter. Capital International Investors grew its stake in shares of Novo Nordisk A/S by 52.4% in the 3rd quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after buying an additional 6,092,192 shares in the last quarter. Boston Partners bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $310,199,000. Price T Rowe Associates Inc. MD increased its holdings in Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock worth $492,940,000 after buying an additional 4,836,285 shares during the last quarter. Finally, Voloridge Investment Management LLC increased its holdings in Novo Nordisk A/S by 851.6% in the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after buying an additional 4,302,126 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Zacks upgraded Novo Nordisk from “strong sell” to “hold,” a modest vote that may limit further downside from some retail/quant sellers. Read More.
• Positive Sentiment: Novo entered a WHO Foundation partnership focused on cardio‑renal‑metabolic diseases and committed funding for obesity/diabetes efforts in low‑ and middle‑income countries — a reputational and long‑term access play that supports the company’s global public‑health positioning. Read More.
• Neutral Sentiment: Novo Holdings published 2025 annual results showing income and investment returns; while the report is routine, its figures are being viewed through the lens of Novo Nordisk’s share‑price swing. Read More.
• Neutral Sentiment: India’s regulator warned drugmakers about direct or surrogate advertising for weight‑loss drugs, a policy development that adds regulatory complexity across a large and fast‑growing market but is industry‑wide rather than Novo‑specific. Read More.
• Negative Sentiment: FDA issued a warning letter over failures in post‑marketing adverse event reporting tied to semaglutide, triggering immediate regulatory risk and heightened compliance scrutiny that can hurt investor confidence and valuation. Read More.
• Negative Sentiment: Regulatory news sparked sharp market reaction and legal attention: a class‑action/investor probe (Pomerantz) was announced and some articles report a very steep intraday drop tied to the FDA news, increasing the chance of litigation and reputational/financial fallout. Read More.
• Negative Sentiment: Analysts have reacted: TD Cowen and others trimmed ratings/targets, and coverage notes the hit to Novo Holdings’ controlling‑shareholder asset value — both amplify selling pressure. Read More.
• Negative Sentiment: Competitive pressure from Eli Lilly (big investments and programs to expand GLP‑1 access) is a strategic negative for Novo’s long‑term market share and pricing power in GLP‑1s. Investors should factor stronger Lilly initiatives into longer‑term growth forecasts. Read More.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.